Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 17/20 | 0.71 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752044 | 0.84 | APP (1.00) | APPSULT1A1MAPTGLAGAA | |
| SCHEMBL22009035 | 0.81 | APP (0.67) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13853555 | 0.81 | APP (0.94) | APPSULT1A1MAPTGLAGAA | |
| SCHEMBL13096107 | 0.80 | APP (0.65) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13806297 | 0.79 | APP (0.84) | APPSULT1A1MAPTGLAGAA | |
| SCHEMBL12421910 | 0.77 | APP (0.85) | APPSULT1A1MAPTGLAGAA | |
| SCHEMBL29581521 | 0.77 | APP (0.80) | APPSULT1A1MAPTGLAGAA | |
| SCHEMBL5423269 | 0.76 | APP (0.81) | APPSULT1A1MAPTGLAGAA | |
| SCHEMBL13096109 | 0.75 | APP (0.65) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL21754474 | 0.75 | APP (0.61) | APPSULT1A1MAPTTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | DEBRECENI EGYETEM (HU) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894096-B2 | 3,6,9, 15-tetraaza-bicyclo [9.3.1]pentadeca-1(14), 11(15), 12-triene based compounds and their application as ligands of essential metal ion based MRI and 52MN based PET contrast agents | SLC39A14, SLC39A11, TMEM14C | APP 2972/4885SULT1A1 2120/4885MAPT 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.